Quantcast

Latest Philadelphia chromosome Stories

2010-03-03 13:28:02

An international team of scientists studying acute forms of Leukaemia have identified a new drug target to inhibit the genes which are vital for the growth of diseased cells. The research, reported in EMBO Molecular Medicine, reveals how leukaemia cells become 'addicted' to genes, which if targeted could prevent diseased cells from developing. The team, led by Dr Veronika Sexl from the University of Vienna, carried out their research on acute lymphoid leukaemia (ALL) and chronic myelogenous...

2010-02-19 00:32:00

EAST HANOVER, N.J., Feb. 19 /PRNewswire/ -- Novartis announced today that Tasigna® (nilotinib) 200 mg capsules has been granted priority review by the US Food and Drug Administration (FDA) for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. FDA priority review status is granted to therapies that offer major advances in treatment or provide a treatment where no adequate therapy...

2009-12-08 08:29:00

FRIMLEY, England, December 8 /PRNewswire/ -- - Nilotinib Surpassed imatinib in Key Measures of Treatment Effectiveness in the Trial, in Patients With Newly-Diagnosed Disease(1) - At 12-Months, Significantly Fewer Patients Progressed to Later Stages of the Disease on nilotinib (300mg Twice-Daily and 400mg Twice-Daily) Than on imatinib 400mg Once-Daily(1) - Nilotinib was Generally Well Tolerated; Only a Small Number of Patients Discontinued Due to Adverse Events(1) -...

2009-12-08 08:15:00

EAST HANOVER, N.J., Dec. 8 /PRNewswire/ -- In a large Phase III clinical trial, Tasigna® (nilotinib) 200 mg capsules demonstrated greater efficacy over Gleevec® (imatinib mesylate) tablets* in the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase(1). To view the multimedia assets associated with this release, please click:...

2009-12-07 18:45:30

Two medications approved as treatment for drug-resistant chronic myeloid leukemia continue to provide patients with quicker, better responses as a first treatment than the existing front-line drug, researchers at The University of Texas M. D. Anderson Cancer Center reported at the 51st Annual Meeting of the American Society of Hematology. Initial therapy for CML remains imatinib, a Novartis drug known as Gleevec®, which has increased the five-year survival rate for the...

2009-12-05 08:00:00

Leukemia and myeloproliferative disorders are serious and often deadly blood cancers. Research presented today at the 51st Annual Meeting of the American Society of Hematology introduces potential new treatment options and improved diagnostic methods for patients suffering from acute promyelocytic leukemia, chronic myeloid leukemia, infant acute lymphoblastic leukemia, and myelofibrosis that are based on a better understanding of the underlying genetic causes of these conditions. "Researchers...

2009-12-05 10:00:00

Omacetaxine launches different attack on CML that is impervious to other therapies NEW ORLEANS "• Results from a phase II clinical trial indicate a novel drug may provide a treatment option for chronic myeloid leukemia (CML) patients who do not respond to current therapies, researchers from The University of Texas M. D. Anderson Cancer Center report today at the 51st Annual Meeting of the American Society of Hematology. The injectable drug omacetaxine achieved durable responses in some...

2009-12-05 08:30:00

NEW ORLEANS, Dec. 5 /PRNewswire-USNewswire/ -- Leukemia and myeloproliferative disorders are serious and often deadly blood cancers. Research presented today at the 51st Annual Meeting of the American Society of Hematology introduces potential new treatment options and improved diagnostic methods for patients suffering from acute promyelocytic leukemia, chronic myeloid leukemia, infant acute lymphoblastic leukemia, and myelofibrosis that are based on a better understanding of the underlying...

2009-12-02 17:45:00

NEW YORK, Dec. 2 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Kinase Inhibitors: Global Markets http://www.reportlinker.com/p0166819/Kinase-Inhibitors-Global-Markets.html Forecasts for the global market, providing data for the years 2005 through 2008, and projections for the market and compound annual growth rates (CAGRs) through 2014 An overview of the market for the kinase inhibitor class of drugs that already are...

2009-12-01 06:30:00

SOUTH SAN FRANCISCO, Calif., Dec. 1 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that eleven presentations on preclinical studies of the company's product candidates will be given at the upcoming American Society of Hematology (ASH) Meeting and Exposition in New Orleans, Louisiana from December 5-8, 2009. Rigel's R788, an oral Syk kinase inhibitor, will be discussed in two oral presentations by collaborators about its activity in distinct B-cell...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related